Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507022 | 0.83 | HRH3 (0.55) | SIGMAR1HRH3KCNH2SLC6A3HTR2C | |
| SCHEMBL3987646 | 0.83 | HRH3 (0.69) | SIGMAR1HRH3KCNH2SLC6A3 | |
| SCHEMBL30446884 | 0.81 | CA2 (0.57) | — | |
| SCHEMBL4117753 | 0.78 | HRH1 (0.67) | HRH1SIGMAR1SCN5AHRH3LTA4H | |
| SCHEMBL18917604 | 0.77 | LTA4H (0.75) | HRH1SIGMAR1SCN5AHRH3LTA4H | |
| SCHEMBL4993786 | 0.77 | HRH3 (0.77) | HRH1SIGMAR1HRH3KCNH2 | |
| SCHEMBL22561783 | 0.77 | HRH3 (0.74) | HRH1SIGMAR1SCN5AHRH3KCNH2 | |
| SCHEMBL4991238 | 0.77 | HRH1 (0.70) | HRH1SIGMAR1SCN5AHRH3LTA4H | |
| SCHEMBL10642989 | 0.77 | HRH1 (0.60) | HRH1SIGMAR1SCN5AHRH3LTA4H | |
| SCHEMBL9625455 | 0.77 | HRH1 (0.60) | HRH1SIGMAR1SCN5AHRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| EP-3181554-A1 | QUINAZOLINE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | HRH1 2539/4885SIGMAR1 1292/4885SCN5A 1383/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | HRH1 2539/4885SIGMAR1 1292/4885SCN5A 1383/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | HRH1 2539/4885SIGMAR1 1292/4885SCN5A 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.